Some visit links earn us a commission.

Lowest compounded tirzepatide drug price in New Jersey 2026: $69 a month, plus yearly membership

Compounded tirzepatide, a pharmacy-made version that is not Zepbound or Mounjaro, ships to New Jersey from four of our partner programs. The lowest of the programs we track is $69 a month at Collective, plus a yearly membership, read on November 11, 2026.

Medicaid for weight loss
Not covered
Partner programs that ship here
Eden, Collective, SnagRx and CoreAge Rx
Adults with obesity
27.0% (CDC, 2025)

Compounded tirzepatide prices in New Jersey

ProgramMonthly priceCheckedProgram's site
Eden logoEden$129 a monthNovember 11, 2026Check price →
Collective logoCollective$69 a month, plus yearly membershipNovember 11, 2026Check price →
SnagRx logoSnagRx$149 a month, or $119 a month paid 12 months up frontNovember 11, 2026
CoreAge Rx logoCoreAge Rx$129 a monthNovember 11, 2026

Eden, Collective, SnagRx and CoreAge Rx pay GLP Chart when you buy through our links.

What a year of compounded tirzepatide costs in New Jersey

  • Eden ships to New Jersey at $1,548 for 12 months.
  • Collective ships to New Jersey at $1,027 for 12 months with its membership.
  • SnagRx ships to New Jersey at $1,788 for 12 months, or $1,428 if New Jersey buyers pay 12 months up front.
  • CoreAge Rx ships to New Jersey at $1,548 for 12 months.

For compounded semaglutide, New Jersey buyers pay from $59 a month at Collective, plus a yearly membership, against $69 for compounded tirzepatide in New Jersey.

Does NJ FamilyCare (New Jersey Medicaid) cover Zepbound?

NJ FamilyCare (New Jersey Medicaid) does not cover Zepbound for weight loss. It does cover Zepbound for obstructive sleep apnea, with prior authorization. New Jersey Medicaid plans include Horizon NJ Health, UnitedHealthcare Community Plan NJ, WellCare NJ (Centene) and Aetna Better Health of New Jersey. No New Jersey Medicaid plan pays for compounded tirzepatide, so it is a cash purchase. New Jersey Medicaid GLP-1 rules.

Obesity in New Jersey

27.0% of adults in New Jersey had obesity in 2025, by the CDC's state survey, against 33.5% for the US as a whole. That puts New Jersey 6.5 points below the national rate, about 3 in 10 New Jersey adults.

More for New Jersey

Compounded tirzepatide is made by a licensed pharmacy to a prescription and is not FDA-approved. A prescriber decides whether it suits you.